Κλαύδιος Γαληνός
Δωρεάν εγγραφή Αποκτήσετε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr για έναν μήνα
Έλεγχος συγχορήγησης Ελέγξτε την αγωγή σας για αντενδείξεις και αλληλεπιδράσεις μεταξύ των φαρμάκων
Μητρότητα και φάρμακα Ενημερωθείτε για την ασφάλεια χορήγησης ενός φαρμάκου κατά τη διάρκεια της εγκυμοσύνης ή του θηλασμού
Συνδρομές Μάθετε περισσότερα για τα οφέλη και τις επιπλέον παροχές των συνδρομητικών προγραμμάτων
Ενδείξεις και αγωγές Βρείτε θεραπευτικές ενδείξεις και αγωγές για νόσους, συμπτώματα και ιατρικές πράξεις
Γνωρίζατε ότι... Μοιραζόμαστε μαζί σας γεγονότα της πορείας του Galinos.gr από το 2011 μέχρι σήμερα

Rythmodan 100mg Capsules (2011)

Αναφορές

Βιβλιογραφική αναφορά

Στοιχεία εκδότη

Εκδότης SANOFI
Διεύθυνση 1 Onslow Street, Guildford, Surrey, GU1 4YS, UK
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή

Name of the medicinal product

Rythmodan 100mg Capsules.

Qualitative and quantitative composition

Capsule containing Disopyramide 100mg. For excipients, see section 6.1.

Pharmaceutical form

Capsule.

Therapeutic indications

Rythmodan is used in the treatment of cardiac arrhythmias as follows: The prevention and treatment of arrhythmias occurring after myocardial infarction. Maintenance of normal rhythm following electroconversion ...

Posology and method of administration

Route of administration Oral. 300 mg to 800mg daily in divided doses. Children Not recommended as insufficient data available. Elderly A dose reduction due to reduced renal and hepatic function in the ...

Contraindications

Disopyramide is contra–indicated in un–paced second or third degree atrioventricular block; bundle–branch block associated with first–degree atrioventricular block ; unpaced bifasicular block; pre-existing ...

Special warnings and precautions for use

Antiarrhythmic drugs belonging to the class 1c (Vaughan Williams Classification) were included in the Cardiac Arrhythmia Suppression Trial (CAST), a long term multicentre randomised, double blind study ...

Interaction with other medicinal products and other forms of interaction

Combination with other antiarrhythmic drugs: Combinations of antiarrhythmic drugs are not well researched and their effect may be unpredictable. Thus, antiarrhythmic combination should be avoided except ...

Pregnancy and lactation

Pregnancy Although Rythmodan has undergone animal tests for teratogenicity without evidence of any effect on the developing foetus, its safety in human pregnancy has not been established. Rythmodan has ...

Effects on ability to drive and use machines

Some adverse reactions may impair the patients ability to concentrate and react, and hence the ability to drive or operate machinery. (See section 4.8).

Undesirable effects

Cardiac: It is accepted that the arrhythmogenic potential of disopyramide is weak. However, as with all antiarrhythmic drugs, disopyramide may worsen or provoke arrhythmias. This proarrhythmic effect is ...

Overdose

There is no specific antidote for disopyramide. Prostigmine derivatives can be used to treat anticholinergic effects. Symptomatic supportive measures may include: early gastric lavage; administration of ...

Pharmacodynamic properties

Class 1 anti-arrhythmic agent. It decreases membrane responsiveness, prolongs the effective refractory period (ERP) and slows automaticity in cells with augmented automaticity. Effective refractory period ...

Pharmacokinetic properties

Elimination phase of plasma t<sub>1/2</sub>: 5-8 hours. Increased in hepatic impairment, cardiac and hepatic disease. Protein binding: 50 60%. Saturable and concentration dependent. Volume of distribution: ...

Preclinical safety data

Not applicable.

List of excipients

Maize starch Magnesium stearate STA-RX 1500 (pregelatinised starch) Talc Capsule shell: Gelatin Indigo carmine Iron oxide and Titanium dioxide (E171)

Incompatibilities

Not known.

Shelf life

PVC Blister: 36 months.

Special precautions for storage

Do not store above 25°C.

Nature and contents of container

Sanofi-aventis One Onslow Street Guildford Surrey GU1 4YS UK

Nature and contents of container

PVC Blister containing 84 capsules.

Special precautions for disposal and other handling

None.

Marketing authorization number(s)

PL 04425/0607

Date of first authorization / renewal of the authorization

12 February 2009

Date of revision of the text

24 February 2010
Μπορείτε να υποστηρίξετε τον Γαληνό στην αποστολή του να παρέχει δωρεάν έγκυρη πληροφόρηση για κάθε φάρμακο απενεργοποιώντας το Ad Blocker για αυτόν τον ιστότοπο.